Prophylaxis will not work for any Abs if there is no distribution/penetration into lung/upper respiratory system...so, idea tu burst Abs level in lungs (because of the larger increase of the viral titer, as disease advance) is fundamental problem. At least 10X proph. dose level needed, I guess. Nebulizer for Abs is still not the best idea, IMO.
< Am I missing anything else about this that we should take away from it?>
Cross reactivity (SARS/MERS) for ACE2/RBD binding assay was not observed, while for the viral binding assay (not viral neutralization assay, viral binding at distant epitopes, outside RBD) cross reactivity was partially demonstrated (SARS preferential).
Unknown mutation rate and at what position(s), that will effect vaccine/Abs development? Obviously, epitopes on RBD responsible for ACE2 complex are not conserved! One need to study mutation rates on those epitopes, and how may effect virulence (or viral self-destruction), as well as drug development.
China scientist are on right path, IMO.
PS: If nCoV show same rate of the new strain as flu does, all betts ( cards) are off. |
